Radiopharm Theranostics Doses First Patient in Phase 1 Study for Advanced Prostate Cancer Drug RAD 402
Summary
Radiopharm Theranostics announced the dosing of the first patient in its Phase 1 clinical trial for RAD 402, an investigational radiotherapeutic for advanced prostate cancer. This marks a significant step in advancing its pipeline.
Key Events
-
Phase 1 Clinical Trial Initiation
Radiopharm Theranostics has dosed the first patient in its Phase 1 clinical study (NCT07259213) for RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161, for advanced prostate cancer.
-
Focus on Safety and Tolerability
The Phase 1 study is designed to evaluate the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402, aiming to determine the Maximum Tolerated Dose (MTD) and/or recommended Phase 2 dose (RP2D).
-
Data Expected in 2H 2026
The company is on track to share data from the first two dose levels of the RAD 402 study in the second half of 2026.
Analysis
This filing signals a positive progression in Radiopharm Theranostics' pipeline, as it initiates a new clinical trial for RAD 402, a novel radiotherapeutic targeting KLK3 in advanced prostate cancer. Dosing the first patient in a first-in-human Phase 1 study is a key milestone, demonstrating the company's ability to advance its drug candidates into clinical development. Investors will be watching for the data from the first two dose levels, expected in the second half of 2026, to assess the safety and preliminary activity of RAD 402. This follows recent positive Phase 2b data for another candidate, RAD 101, indicating active pipeline development.
At the time of this filing, RADX was trading at $4.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.8M. The 52-week trading range was $3.50 to $16.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.